Direct-acting antivirals (DAAs) are effective for chronic hepatitis C even in elderly adults, resulting in respectable rates sustained virological response (SVR) independently of age, a recent study has shown.
Patients with nonalcoholic fatty liver disease (NAFLD) may develop significant fibrosis in the absence of nonalcoholic steatohepatitis (NASH), with risk factors including fasting hyperglycaemia, severe steatosis, mild inflammation and the PNPLA3 I148M variant, according to a recent study.
Nivolumab, used in the first-line treatment of patients with advanced hepatocellular carcinoma (HCC), has demonstrated clinically meaningful improvements in overall survival (OS) and response rates vs sorafenib in the phase III CheckMate 459 study, although the improvement in OS did not reach statistical significance.
Intelligent Liver Function Testing (iLFT), an automated investigation algorithm for liver function tests (LFTs), is highly cost-effective, leading to higher rates of liver diagnoses and improvements in quality of care, according to a new study.
In autoimmune hepatitis (AIH) patients receiving induction therapy with prednisone or prednisolone, the dose to induce remission may be lowered without compromising efficacy, as reported in a recent study. Specifically, 0.50 mg/kg/day is enough and hence reduces unnecessary exposure to the drugs in this population.